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Widening Horizon of Pharmacoeconomics and Outcomes Research in
the Asia-Pacific RegionIn keeping in line with most other Western countries, the demand
for health care is continuously rising in Asia, which includes a
growth in personal income, an aging population, increase in the
prevalence of some noncommunicable diseases, individuals’
growing awareness of better health status, and introduction of
new health technologies. The greatest demand, however, is pop-
ulation growth, contributing to a greater demand for health care
resources, particularly in the developing Asian economies. A nat-
ural consequence of these dynamics is resource scarcity in health
care delivery in most of the countries, namely, countries that do
not have enough resources to meet peoples’ rising expectation of
resource use. A more practical challenge that each country’s
health care system faces is the deepening health budget con-
straint. Policymakers and stakeholders in health financing are
deeply concerned about the difficulties involved. This difficulty is
more vivid in China mainland, Japan, Korea, Singapore, Taiwan,
Thailand, Indonesia, and Malaysia, and it is probably fair to say
that there is hardly any country in Asia that can be exempted from
this situation.
In finding a solution for long-term financial sustainability of
health financing, health authorities started eyeing the health
technology sector, including pharmaceuticals, devices and diag-
nostics, and treatment procedures. A development globally ob-
served starting with the United Kingdom, Canada, and Australia
has been the introduction of the health technology assessment
(HTA) system for pharmaceutical pricing and reimbursement for
drug formulary. Asia in that regard is no exception. Several ju-
risdictions in Asia recently introduced a system requiring the
generation and utilization of pharmacoeconomic data as evi-
dence for decisions in the use of the scarce health resources.
Starting with South Korea in 2007, the concept of HTA has been
formally introduced in the region, and formalizing HTA is be-
coming a trend in Asia.
This trend becomes vivid when one looks at the HTA position-
ing of countries in Asia [1]. Areas where one or more regulatory
bodies are developing include South Korea (Health Insurance Re-
view and Assessment), Taiwan (Center for Drug Evaluation), and
Thailand (Health Intervention and Technology Assessment Pro-
gram). South Korea is at a slightly more advanced stage with its
pharmacoeconomic guideline, which was recently refined to ac-
commodate local data availability and methodological issues,
though its basic HTA structure and methodology framework re-
main intact [2]. Taiwan has formally made pharmacoeconomic
tudies part of drug listing submission requirements, while Thai-
and has officially used such studies in national drug formulary
ecision making. Countries at the intermediate stage are China,
apan, and Singapore, where either the pharmacoeconomic guide-
ine has been developed (although yet to be adopted officially) orConflicts of interest: The authors have indicated that they have nopharmacoeconomics and outcomes research (PE-OR) data are vol-
untarily submitted. Some other countries, including Malaysia,
Philippines, Pakistan, and India, are in the HTA-developing stage,
looking into the possibility of using PE-OR data for efficient and
equitable use of health technologies [3].
The ISPOR Asia Consortium completed a survey on the needs
for PE-OR in Asia, covering eight Asian countries in 2009. It was
found that many PE-OR methodologies have been adopted and
used in Asia, including cost-effectiveness analysis, decision an-
alytic modeling, and budget impact analysis. As in most West-
ern countries, a special pharmaceutical benefit assessment
committee within the government’s HTA agency is playing a
role in making the formulary decision in those surveyed Asian
countries. The survey also suggests that there is a need for more
PE-OR practical applications, educational training of man-
power, research activities, and government’s formal require-
ment of PE-OR guidelines [4].
Along with this trend in Asia comes a growing attention of
researchers in the area of PE-OR. This is well manifested in the
following two phenomena. First, there are an ever-growing num-
ber of attendees at the ISPOR Asia-Pacific (AP) conferences over
time. For example, at the 1st ISPOR AP Conference in Kobe, Japan,
104 abstracts and proposals were submitted, and 250 people at-
tended the conference as participants. At the ISPOR 2nd AP Con-
ference, which took place in Shanghai, China, the number in-
creased to 234 submissions, with more than 750 conference
participants from 32 countries. At the ISPOR 3rd AP Conference in
Seoul, South Korea, the number reached a total of 298 submis-
sions, with more than 859 conference attendees from 35 countries.
Last, at the ISPOR 4th AP Conference in Phuket, Thailand, there
were 413 submissions, with more than 812 participants from 38
countries. It is clear that more and more people are keen to par-
ticipate in ISPOR AP conferences, where they can present their
research findings as well as learn what others have discovered
through their studies. The ISPOR AP conferences have emerged as
an important scientific event where experts gather, share study
findings, learn from others, and exchange views on science and
technology–related health policies.
Another interesting related development was the substantial
number of manuscripts submitted for publication in the Value in
Health (ViH) Asia Special Issues. ISPOR and the ISPOR Asia Consor-
tium subsequently decided to publish these issues with the pur-
pose of making available the key findings/exchanges from the
immediate past ISPOR AP Conference to the audience, but submis-
sions for publication in the special issue were open to any re-
searchers from the region or any topics covering the region.
Against this background, the first ViH Asia special issue was pub-
lished in 2008, carrying articles from the ISPOR 2nd AP Conferenceconflicts of interest with regard to the content of this article.
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region, the second special issue in 2009 following the 3rd AP Con-
ference (Seoul, South Korea), and the third special issue in 2012
(ViH, Volume 15, Supplement 1, January/February 2012) after the
4th AP Conference (Phuket, Thailand).
What is remarkable is the rapidly growing number of submis-
sions for publication in the ViH Asia Special Issues, suggesting a
growth in academic interest in PE-OR research in this region. We
believe that this increase in the number of submissions is mainly
driven by stakeholders, where stakeholders encompass decision
makers, industry, researchers, and health practitioners. Although
the number of published articles in each special issue remained
somewhat limited (22 articles for the first issue, 24 for the second
issue, and 20 for the 3rd issue), the number of submissions sky-
rocketed from 36 submissions for the first issue to 48 for the sec-
ond issue to 116 for the third issue. The article rejection rate, as a
result, also increased from 39% for the first Issue to 50% for the
second Issue to 83% for the third Issue. A rejection rate as high as
83% clearly signaled a need for an increase in the demand for
publication of PE-OR research in the Asia region.
In the face of this challenge of rapidly growing scientific re-
search on PE-OR but with small room for publishing their findings,
ISPOR and the ISPOR Asia Consortium, along with the ISPOR Latin
America Consortium, decided that a new independent PE-OR jour-
nal should be made available to cater to research coming from
regions other than Europe and North America. This new venture is
titled Value in Health Regional Issues (ViHRI). From the background
of ViHRI, it is evident that, first, the new journal aims at accom-
modating the growing demand for PE-OR research from this re-
gion; second, to encourage researchers in each region to carry out
more quality scientific research; and third, to help countries in
each region establish their own version of PE-OR research guide-
line and policy. Now it is up to us—regional researchers, policy-
makers, and health care practitioners—to set up our own research
agendas, to produce what we need, and to proceed with science
and policy development. The venue for all these to happen is the
ViHRI, and all of us are the key to achievements and success.
The use of HTA in health care delivery is the track that every
country in Asia is interested in and is contemplating to follow in
the future, with some country-level variances in its stage of frame-
work adoption. A natural consequence of this track is the growing
need for evidence generation. We believe that the launch of ViHRIis a promising, if not certain, way of meeting such a need, both in
Asia and in Latin America. This would be long-running project, but
as long as we hold on to the principle of inviting and publishing
good research findings from each region, which is to be the prime
responsibility of whole editorial staff in charge, the future will be
undoubtedly with us.
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